Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
Zomedica has launched a new equine insulin assay for its TRUFORMA In-Clinic Biosensor Testing Platform. The assay provides quantitative insulin level detection in equine plasma with results in just 18 minutes, enabling quick diagnosis and monitoring of insulin dysregulation in horses. This third equine-focused assay complements Zomedica's existing eACTH test, helping veterinarians diagnose conditions like Equine Metabolic Syndrome (EMS) and Pituitary Pars Intermedia Dysfunction (PPID), which affect 18-27% of ponies and horses. The point-of-care solution eliminates reference laboratory wait times and requires no capital outlay or monthly minimums from veterinary practices.
Zomedica ha lanciato un nuovo assay di insulina equina per la sua piattaforma di test biosensore in clinica TRUFORMA. L'assay fornisce la rilevazione quantitativa dei livelli di insulina nel plasma equino con risultati in soli 18 minuti, consentendo una diagnosi rapida e un monitoraggio della disregolazione dell'insulina nei cavalli. Questo terzo assay focalizzato sugli equini integra il test eACTH esistente di Zomedica, aiutando i veterinari a diagnosticare condizioni come il Sindrome Metabolica Equina (EMS) e la Disfunzione della Pars Intermedia Pituitaria (PPID), che colpiscono il 18-27% dei pony e dei cavalli. La soluzione point-of-care elimina i tempi di attesa nei laboratori di riferimento e non richiede investimenti iniziali o minimi mensili da parte delle pratiche veterinarie.
Zomedica ha lanzado un nuevo ensayo de insulina equina para su plataforma de pruebas biosensor TRUFORMA en clínica. El ensayo proporciona la detección cuantitativa de los niveles de insulina en plasma equino con resultados en solo 18 minutos, lo que permite un diagnóstico rápido y un monitoreo de la disfunción de insulina en caballos. Este tercer ensayo enfocado en equinos complementa la prueba eACTH existente de Zomedica, ayudando a los veterinarios a diagnosticar condiciones como el Síndrome Metabólico Equino (EMS) y la Disfunción de la Pars Intermedia de la Hipófisis (PPID), que afectan entre el 18 y el 27% de los ponis y caballos. La solución point-of-care elimina los tiempos de espera en laboratorios de referencia y no requiere inversión inicial ni mínimos mensuales por parte de las prácticas veterinarias.
조메디카는 TRUFORMA 클리닉 바이오센서 테스트 플랫폼을 위한 새로운 말 인슐린 분석법을 출시했습니다. 이 분석법은 말의 혈장에서 인슐린 수치를 정량적으로 측정하며, 결과를 단 18분 만에 제공하여 말의 인슐린 이상을 신속하게 진단하고 모니터링할 수 있게 합니다. 이 세 번째 말 중심의 분석법은 조메디카의 기존 eACTH 검사를 보완하여 수의사들이 말 대사 증후군 (EMS)과 샘 중간엽 기능장애 (PPID)과 같은 질환을 진단할 수 있도록 도와줍니다. 이 질환들은 18-27%의 포니와 말에 영향을 미칩니다. 이 포인트오브케어 솔루션은 참조 실험실 대기 시간을 없애고, 수의사 사무실에서 초기 투자나 최소 월급을 필요로 하지 않습니다.
Zomedica a lancé un nouveau test d'insuline équine pour sa plateforme de tests de biosenseurs en clinique, TRUFORMA. Le test fournit une détection quantitative du niveau d'insuline dans le plasma équin avec des résultats en seulement 18 minutes, permettant un diagnostic rapide et un suivi de la dysrégulation de l'insuline chez les chevaux. Ce troisième test axé sur les équidés complète le test eACTH existant de Zomedica, aidant les vétérinaires à diagnostiquer des conditions telles que le Syndrome Métabolique Équin (EMS) et la Dysfonction de la Pars Intermédiaire de l'Hypophyse (PPID), qui touchent 18 à 27 % des poneys et chevaux. La solution point-of-care élimine les temps d'attente dans les laboratoires de référence et ne nécessite aucun investissement initial ni minimum mensuel de la part des pratiques vétérinaires.
Zomedica hat einen neuen Insulinassay für Pferde für seine TRUFORMA-In-Clinic-Biosensor-Testplattform eingeführt. Der Assay ermöglicht eine quantitative Insulinspiegelmessung im equinen Plasma und liefert Ergebnisse in nur 18 Minuten, was eine schnelle Diagnose und Überwachung von Insulin-Dysregulation bei Pferden ermöglicht. Diese dritte pferdefokussierte Analyse ergänzt den bestehenden eACTH-Test von Zomedica und hilft Tierärzten, Erkrankungen wie Equines Metabolisches Syndrom (EMS) und Hypophysenmittellappen-Dysfunktion (PPID) zu diagnostizieren, die 18-27% der Ponys und Pferde betreffen. Die Point-of-Care-Lösung eliminiert die Wartezeiten in Referenzlaboren und erfordert keine Investitionskosten oder monatlichen Mindestbeträge von tierärztlichen Praxen.
- Fast 18-minute result turnaround compared to traditional lab testing
- No capital outlay or monthly minimums required from veterinary practices
- Expands product portfolio with third equine-focused assay
- Addresses significant market with 18-27% disease prevalence in horses and ponies
- None.
Insights
The launch of Zomedica's quantitative insulin assay for equine plasma represents a significant advancement in veterinary diagnostics. The 18-minute turnaround time for results marks a dramatic improvement over traditional reference laboratory wait times, which typically take days. This rapid testing capability addresses a critical market need, as equine insulin dysregulation affects
The technology's dual application for both EMS and PPID diagnosis, combined with the existing eACTH assay, creates a comprehensive diagnostic solution. The business model of requiring no capital outlay or monthly minimums reduces barriers to adoption for veterinary practices. This strategic approach could drive market penetration and recurring revenue through test sales. The platform's point-of-care and stall-side flexibility enhances its commercial viability and practical utility.
This product launch strengthens Zomedica's position in the equine diagnostics market through several key advantages:
- First-mover advantage in rapid, point-of-care insulin testing
- Zero-capital investment model that accelerates adoption
- Complementary integration with existing eACTH assay
Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients
ANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its third equine-focused assay - Insulin for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform.
Veterinarians test equine insulin levels when they suspect Equine Metabolic Syndrome (EMS) or other forms of insulin dysregulation, as frequently occurs with equine Cushing's disease, or Pituitary Pars Intermedia Dysfunction (PPID), with prevalence reported between 18
The TRUFORMA Insulin assay offers quantitative detection of insulin levels in equine plasma, with results available in just 18 minutes. This rapid turnaround enables veterinarians to diagnose and monitor insulin dysregulation in horses quickly, eliminating the need for reference laboratory wait times and allowing for immediate treatment decisions. The assay is designed for both in-clinic and stall-side use, providing flexibility for various clinical settings. Importantly, Zomedica offers this advanced diagnostic capability with no capital outlay or monthly minimums from veterinary practices.
Katarzyna Dembek DVM, PhD, DACVIM, Assistant Professor of Equine Internal Medicine at North Carolina State University, stated, "Accurate diagnosis and monitoring of insulin dysregulation is crucial when making treatment decisions for horses with equine metabolic syndrome. Having the TRUFORMA insulin assay available at point-of-care allows those decisions to be made on the spot, rather than waiting days for results from a reference lab."
T.J. Barclay, DVM, a Zomedica Professional Services Veterinarian, commented, "Early identification of horses with insulin dysregulation is key in preventing hyperinsulinemia-associated laminitis. The TRUFORMA insulin assay delivers that critical information within minutes. The combination of TRUFORMA's insulin and eACTH assays can provide the veterinarian with a complete understanding of the patient's laminitis risk, allowing treatment decisions to be made on the spot."
The TRUFORMA Insulin assay for equine plasma may be ordered now from Zomedica. For more information, visit www.zomedica.com.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including acceptance of the TRUFORMA platform or equine insulin assay; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What is the new insulin assay launched by Zomedica (ZOM)?
How long does Zomedica's (ZOM) TRUFORMA insulin test take to show results?
What conditions can Zomedica's (ZOM) new insulin assay detect in horses?
What are the financial requirements for veterinary practices to use Zomedica's (ZOM) TRUFORMA insulin assay?
